Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 5/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRG | P48443 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.31 |
| ▸ | AR | P10275 | 2/20 | 0.30 |
| ▸ | ACLY | P53396 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3602959 | 0.87 | IDH2 (0.38) | IDH2ERBB2ERBB4 | |
| SCHEMBL3596237 | 0.85 | PTGDR2 (0.39) | RXRARXRG | |
| SCHEMBL3594636 | 0.84 | PTGDR2 (0.38) | RXRARXRGDDR1 | |
| SCHEMBL3593302 | 0.84 | PTGDR2 (0.37) | RXRARXRGDDR1 | |
| SCHEMBL4139396 | 0.83 | RXRA (0.35) | RXRARXRG | |
| SCHEMBL4155548 | 0.83 | NPC1 (0.37) | ACLY | |
| SCHEMBL3593299 | 0.83 | RXRA (0.34) | RXRARXRG | |
| SCHEMBL3596958 | 0.83 | L3MBTL1 (0.36) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3597052 | 0.82 | IDH2 (0.36) | IDH2STS | |
| SCHEMBL3597872 | 0.82 | RXRA (0.41) | RXRARXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2010-04-08 | — | — | US | claimed |
| EP-1828172-B1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-11-25 | — | — | EP | claimed |
| EP-1828172-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | Novartis AG (CH) | 2007-09-05 | — | — | EP | claimed |
| WO-2006063763-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2006-06-22 | — | — | WO | claimed |
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2010-04-08 | — | — | US | disclosed |
| EP-1828172-B1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| EP-1828172-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | Novartis AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063763-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087432-A1 | PYRROLE DERIVATIVES HAVING CRTH2 RECEPTOR ANTAGONIST ACTIVITY | PRLHR, AVPR2, CRHR2 | IDH2 1168/4885STS 1766/4885PSEN1 4103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.